Obesity management interventions: A review of the evidence

Population Health Management

Volumn 12, Issue 6, 2009, Pages 305-316

  Yaskin, Joseph ^a   Toner, Richard W ^a   Goldfarb, Neil ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; METFORMIN; PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE;

BEHAVIOR CHANGE; BEHAVIOR MODIFICATION; BLOOD PRESSURE; BODY MASS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; EVIDENCE BASED PRACTICE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEALTH CARE POLICY; HEART RATE; HUMAN; LIFESTYLE MODIFICATION; LOW CALORY DIET; LOW DRUG DOSE; MONOTHERAPY; OBESITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REVIEW; SELF CARE; SIDE EFFECT; SURGICAL TECHNIQUE; WEIGHT REDUCTION;

ADULT; EVIDENCE-BASED PRACTICE; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; WEIGHT LOSS;

EID: 73949083166     PISSN: 19427891     EISSN: 19427905     Source Type: Journal    
DOI: 10.1089/pop.2008.0049     Document Type: Review

References (99)

1. Wang Y, Beydoun MA. The obesity epidemic in the United States-gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev 2007;29:6-28.
2. Daviglus ML, Pirzada A. In the long run, healthcare costs appear to be related to overweight and obesity at younger ages. Expert Review of Pharmacoeconomics and Outcomes Research 2005;5:125-130.
3. Ball K, Crawford D. Socioeconomic status and weight change in adults: a review. Soc Sci Med. 2005;60:1987-2010.
4. Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. JAMA. 2003;289:187-193.
5. Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005;352:1138-1145.
6. Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med. 2001;161:1581-1586.
7. Vazquez G, Duval S, Jacobs DR Jr, Silventoinen K. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a metaanalysis. Epidemiol Rev. 2007;29:115-128.
8. Bhattacharya J, Cutler DM, Goldman DP, et al. Disability forecasts and future medicare costs. Front Health Policy Res. 2004;7:75-94.
9. Andreyeva T, Sturm R, Ringel JS. Moderate and severe obesity have large differences in health care costs. Obes Res. 2004;12:1936-1943.
10. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523-1529.
11. Yanovski SZ, Donato K, Gansheroff L. The obesity epidemic: the role of the National Institutes of Health. Advanced Studies in Medicine. 2005;5:122-123.
12. Gold BC, Burke S, Pintauro S, Buzzell P, Harvey-Berino J. Weight loss on the web: a pilot study comparing a structured behavioral intervention to a commercial program. Obesity (Silver Spring). 2007;15:155-164.
13. Mayer-Davis EJ, D'Antonio AM, Smith SM, et al. Pounds off with empowerment (POWER): a clinical trial of weight management strategies for black and white adults with diabetes who live in medically underserved rural communities. Am J Public Health. 2004;94:1736-1742.
14. Barnard ND, Scialli AR, Turner-McGrievy G, Lanou AJ, Glass J. The effects of a low-fat, plant-based dietary intervention on body weight, metabolism, and insulin sensitivity. Am J Med. 2005;118:991-997.
15. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350. (Pubitemid 32378388)
16. Heshka S, Anderson JW, Atkinson RL, et al. Weight loss with self-help compared with a structured commercial program: a randomized trial. JAMA. 2003;289:1792-1798.
17. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA. 2005;293:43-53.
18. Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: results of the trials of hypertension prevention, phase II. Ann Intern Med. 2001; 134(1):1-11.
19. Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond). 2005;29:1153-1167.
20. American Diabetes Association. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2007;30 suppl 1:S48-S65.
21. Thabane L, Chu R, Cuddy K, Douketis J. What is the quality of reporting in weight loss intervention studies? A systematic review of randomized controlled trials. Int J Obes (Lond). 2007;31:1554-1559.
22. Donnelly JE, Hill JO, Jacobsen DJ, et al. Effects of a 16-month randomized controlled exercise trial on body weight and composition in young, overweight men and women: the midwest exercise trial. Arch Intern Med. 2003;163:1343-1350.
23. Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008;359:229-241.
24. Richardson CR, Newton TL, Abraham JJ, Sen A, Jimbo M, Swartz AM. A meta-analysis of pedometer-based walking interventions and weight loss. Ann Fam Med. 2008;6:69-77.
25. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007;369:71-77.
26. Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for overweight and obesity: A systematic review and metaanalysis of randomized controlled trials. Int J Obes Relat Metab Disord. 2003;27:1437-1446.
27. Rucker D, Padwal R, Li SK, Curioni C, Lau DCW. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335:1194-1199.
28. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353:2111-2120.
29. Poston WSC, Haddock CK, Pinkston MM, et al. Evaluation of a primary care-oriented brief counselling intervention for obesity with and without orlistat. J Intern Med. 2006;260: 388-398.
30. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
31. Bloch KV, Salles GF, Muxfeldt ES, Da Rocha Nogueira A. Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial. J Hypertens. 2003;21:2159-2165.
32. Sjö ström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352(9123):167-172.
33. Anderson JW, Schwartz SM, Hauptman J, et al. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebocontrolled trial. Ann Pharmacother. 2006;40:1717-1723.
34. Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res. 1999;7:189-198.
35. Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord. 2004;28: 1399-1410.
36. Kirov G, Tredget J. Add-on topiramate reduces weight in overweight patients with affective disorders: a clinical case series. BMC Psychiatry. 2005;5:19.
37. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res. 2003;11:722-733.
38. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res. 2002;10:633-641.
39. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients - RIO-North America: a randomized controlled trial. JAMA. 2006;295:761-775.
40. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006;368:1660-1672.
41. Malone DC, Raebel MA, Porter JA, et al. Cost-effectiveness of sibutramine in the LOSE weight study: evaluating the role of pharmacologic weight-loss therapy within a weight management program. J Manag Care Pharm. 2005;11:458-468.
42. Maetzel A, Ruof J, Covington M, Wolf A. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus. Pharmacoeconomics. 2003;21:501-512.
43. Lamotte M, Annemans L, Lefever A, Nechelput M, Masure J. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care. 2002;25:303-308.
44. Brennan A, Ara R, Sterz R, Matiba B, Bergemann R. Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany. Eur J Health Econ. 2006;7(4):276-284.
45. Foxcroft DR. Orlistat for the treatment of obesity: cost utility model. Obes Rev. 2005;6:323-328.
46. Ruof J, Golay A, Berne C, Collin C, Lentz J,Maetzel A. Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland. Int J Obes (Lond). 2005; 29:517-523.
47. Warren E, Brennan A, Akehurst R. Cost-effectiveness of sibutramine in the treatment of obesity. Med Decis Making. 2004;24:9-19.
48. Lacey LA, Wolf A, O'Shea D, Erny S, Ruof J. Costeffectiveness of orlistat for the treatment of overweight and obese patients in Ireland. Int J Obes (Lond). 2005;29:975-982.
49. Zhao Y, Encinosa W. Bariatric surgery utilization and outcomes in 1998 and 2004. Available at: http://www.hcup-us .ahrq.gov/reports/statbriefs/sb23. pdf. Accessed August 27, 2009.
50. Brethauer SA, Chand B, Schauer PR. Risks and benefits of bariatric surgery: current evidence. Cleve Clin J Med. 2006;73:993-1007.
51. Buchwald H, Williams SE. Bariatric surgery worldwide 2003. Obes Surg. 2004;14:1157-1164.
52. Bouldin MJ, Ross LA, Sumrall CD, Loustalot FV, Low AK, Land KK. The effect of obesity surgery on obesity comorbidity. Am J Med Sci. 2006;331:183-193.
53. Kushner RF, Noble CA. Long-term outcome of bariatric surgery: an interim analysis. Mayo Clin Proc. 2006;81(10 suppl):S46-S51.
54. Elder KA, Wolfe BM. Bariatric surgery: a review of procedures and outcomes. Gastroenterology. 2007;132:2253-2271.
55. Shah M, Simha V, Garg A. Review: long-term impact of bariatric surgery on body weight, comorbidities, and nutritional status. J Clin Endocrinol Metab. 2006;91:4223-4231.
56. Encinosa WE, Bernard DM, Chen CC, Steiner CA. Healthcare utilization and outcomes after bariatric surgery. Med Care. 2006;44:706-712.
57. Zingmond DS, McGory ML, Ko CY. Hospitalization before and after gastric bypass surgery. JAMA. 2005;294:1918-1924.
58. Jones KB Jr, Afram JD, Benotti PN, et al. Open versus laparoscopic Roux-en-Y gastric bypass: a comparative study of over 25,000 open cases and the major laparoscopic bariatric reported series. Obes Surg. 2006;16:721-727.
59. Korenkov M. Bariatric surgery. Contrib Nephrol. 2006;151: 243-253.
60. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004; 292:1724-1737.
61. Dixon JB, Strauss BJ, Laurie C, O'Brien PE. Changes in body composition with weight loss: obese subjects randomized to surgical and medical programs. Obesity (Silver Spring). 2007;15:1187-1198.
62. Parikh M, Lo H, Chang C, Collings D, Fielding G, Ren C. Comparison of outcomes after laparoscopic adjustable gastric banding in African-Americans and whites. Surg Obes Relat Dis. 2006;2:607-610; discussion 610-612. (Pubitemid 44804154)
63. Livingston EH, Langert J. The impact of age and Medicare status on bariatric surgical outcomes. Arch Surg. 2006;141:1115-1120; discussion 1121.
64. Sugerman HJ, DeMaria EJ, Kellum JM, Sugerman EL, Meador JG, Wolfe LG. Effects of bariatric surgery in older patients. Ann Surg. 2004;240:243-247.
65. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683-2693.
66. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741-752.
67. Angrisani L, Lorenzo M, Borrelli V. Laparoscopic adjustable gastric banding versus Roux-en-Y gastric bypass: 5-year results of a prospective randomized trial. Surg Obes Relat Dis. 2007;3:127-32; discussion 132-133
68. Galvani C, Gorodner M, Moser F, et al. Laparoscopic adjustable gastric band versus laparoscopic Roux-en-Y gastric bypass: ends justify the means? Surg Endosc. 2006;20:934-941.
69. Kim TH, Daud A, Ude AO, et al. Early U.S. outcomes of laparoscopic gastric bypass versus laparoscopic adjustable silicone gastric banding for morbid obesity. Surg Endosc. 2006;20:202-209.
70. Ballantyne GH, Svahn J, Capella RF, et al. Predictors of prolonged hospital stay following open and laparoscopic gastric bypass for morbid obesity: body mass index, length of surgery, sleep apnea, asthma, and the metabolic syndrome. Obes Surg. 2004;14:1042-1050.
71. Jan JC, Hong D, Bardaro SJ, July LV, Patterson EJ. Comparative study between laparoscopic adjustable gastric banding and laparoscopic gastric bypass: single-institution, 5-year experience in bariatric surgery. Surg Obes Relat Dis. 2007;3:42-50; discussion 50-51
72. Mognol P, Chosidow D, Marmuse JP. Laparoscopic gastric bypass versus laparoscopic adjustable gastric banding in the super-obese: a comparative study of 290 patients. Obes Surg. 2005;15:76-81.
73. Colquitt J, Clegg A, Loveman E, Royle P, Sidhu MK. Surgery for morbid obesity. Cochrane Database Syst Rev. 2005;(4): CD003641.
74. Epidemic of obesity fuels demand among payers for alternatives to bariatric surgery. Disease management advisor. 2003;9:146-149, 141.
75. Nguyen NT, Goldman C, Rosenquist CJ, et al. Laparoscopic versus open gastric bypass: a randomized study of outcomes, quality of life, and costs. Ann Surg. 2001;234:279-89; discussion 289-291
76. Nguyen NT, Gelfand DV, Zainabadi K. Laparoscopic Roux-en-Y gastric bypass vs. laparoscopic adjustable gastric banding for treatment of morbid obesity. Surg Technol Int. 2004;12:111-119.
77. Puzziferri N, Austrheim-Smith IT, Wolfe BM, Wilson SE, Nguyen NT. Three-year follow-up of a prospective randomized trial comparing laparoscopic versus open gastric bypass. Ann Surg. 2006;243:181-188.
78. Buchwald H; Consensus Conference Panel. Consensus conference statement bariatric surgery for morbid obesity: health implications for patients, health professionals, and third-party payers. Surg Obes Relat Dis. 2005;1:371-381.
79. Powers KA, Rehrig ST, Jones DB. Financial impact of obesity and bariatric surgery. Med Clin North Am. 2007;91:321-338, ix.
80. Salem L, Jensen CC, Flum DR. Are bariatric surgical outcomes worth their cost? A systematic review. J Am Coll Surg. 2005;200:270-278.
81. Craig BM, Tseng DS. Cost-effectiveness of gastric bypass for severe obesity. Am J Med. 2002;113:491-498.
82. DiGregorio JM, Palkoner R. Quality of life after obesity surgery, an evidence-based medicine literature review: how to improve systematic searches for enhanced decision-making and clinical outcomes. Obes Surg. 2001;11:318-326.
83. Lee WJ, Wang W, Yu PJ, Wei PL, Huang MT. Gastrointestinal quality of life following laparoscopic adjustable gastric banding in Asia. Obes Surg. 2006;16:586-591.
84. Lee WJ, Yu PJ, Wang W, Lin CM, Wei PL, Huang MT. Gastrointestinal quality of life following laparoscopic vertical banded gastroplasty. Obes Surg. 2002;12:819-824; discussion 825.
85. Mathus-Vliegen EM. Long-term health and psychosocial outcomes from surgically induced weight loss: results obtained in patients not attending protocolled follow-up visits. Int J Obes (Lond). 2007;31:299-307.
86. Torquati A, Lutfi RE, Richards WO. Predictors of early quality-of-life improvement after laparoscopic gastric bypass surgery. Am J Surg. 2007;193:471-475. (Pubitemid 46412235)
87. Foust RF, Burke R, Gordon N. Best practice for obesity and weight management: finding success through linking effective gastric bypass surgery policy and health management. Dis Manag. 2006;9:182-188.
88. Sidorov JE, Fitzner K. Obesity disease management opportunities and barriers. Obesity. 2006;14:645-649.
89. Ricci JA, Chee E. Lost productive time associated with excess weight in the U.S. workforce. J Occup Environ Med. 2005;47:1227-1234.
90. Histon TM, Goeldner JL, Bachman KH, Rothert K. Kaiser Permanente's disease management approach to addressing the obesity epidemic. J Clin Outcomes Manag. 2005;12:464-469.
91. Obesity DM begins to take the shape of more traditional programming. Disease Management Advisor. 2006;12(7):76- 79, 73.
92. Carels RA, Darby L, Cacciapaglia HM, et al. Using motivational interviewing as a supplement to obesity treatment: a stepped-care approach. Health Psychol. 2007;26:369-374.
93. Corella D, Arnett DK, Tsai MY, et al. The-256T>C polymorphism in the apolipoprotein A-II gene promoter is associated with body mass index and food intake in the genetics of lipid lowering drugs and diet network study. Clinical Chemistry. 2007;53:1144-1152.
94. Radha V, Vimaleswaran KS, Ayyappa KA, Mohan V. Association of lipoprotein lipase gene polymorphisms with obesity and type 2 diabetes in an Asian Indian population. Int J Obes (Lond). 2007;31:913-918.
95. Reynolds RM, Walker BR. Can cortisol predict the future in obesity? Clin Endocrinol (Oxf ). 2007;67:1-2.
96. Travison TG, O'Donnell AB, Araujo AB, Matsumoto AM, McKinlay JB. Cortisol levels and measures of body composition in middle-aged and older men. Clin Endocrinol (Oxf ). 2007;67:71-77.
97. Eikelis N, Esler M. The neurobiology of human obesity. Exp Physiol. 2005;90:673-682.
98. Jeffery RW, Linde JA, Finch EA, Rothman AJ, King CM. A satisfaction enhancement intervention for long-term weight loss. Obesity. 2006;14:863-869.
99. Christakis NA, Fowler JH. The spread of obesity in a large social network over 32 years. N Engl J Med. 2007;357:370-379.